Loading, Please Wait...
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (Avedro) today announced the inclusion of a wide range of corneal cross-linking and keratoconus scientific and educational programs at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting held May 3-7 in San Diego, CA, demonstrating significant interest in the diagnosis and treatment of the keratoconus patient population. Keratoconus is a debilitating eye disease that, if left untreated, can lead to loss of vision and even blindness. ASCRS is the largest U.S. meeting dedicated to the needs of anterior segment surgeons (eg., Cornea Specialists and Refractive Surgeons), practice management staff, and ophthalmic technicians and nurses.
At the ASCRS Annual Meeting, there will be more than 80 presentations about corneal cross-linking and keratoconus, in addition to several educational events focused on corneal cross-linking and supported by Avedro. Avedro will also be hosting a series of in-booth peer-to-peer lectures and satellite symposium presented by company representatives and a wide range of key opinion leaders in ophthalmology.
“We are excited by the sheer volume and quality of this year’s scientific sessions on corneal cross-linking,” said Reza Zadno, PhD, President and Chief Executive Officer (CEO) of Avedro. “These presentations, coupled with Avedro’s robust educational programs, will help cornea specialists, technicians and administrators improve treatment techniques as well as reimbursement efficiencies, while updating them on potential future applications of our technology.”
Avedro-sponsored programs are scheduled as follows:
Saturday, May 4
Sunday, May 5
In addition to the above-noted programs, Avedro’s CEO, Reza Zadno, and Chief Medical Officer, Dr. Raj Rajpal, will participate in two panel discussions during the Ophthalmology Innovation Summit (OIS) taking place on Thursday, May 2, at the Hilton San Diego Bayfront. These panel discussions are as follows:
All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.
About Avedro, Inc.
Avedro is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro’s proprietary Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking.
IMPORTANT SAFETY INFORMATION
Photrexa Viscous® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are used with the KXL® System in corneal cross-linking to treat eyes in which the cornea, the clear dome-shaped surface that covers the front of the eye, has been weakened from the progression of the disease keratoconus or following refractive surgery, a method for correcting or improving your vision.
Tell your healthcare provider if you are pregnant or plan to become pregnant.
IMPORTANT SAFETY INFORMATION
Ulcerative keratitis, a potentially serious eye infection, can occur. Your doctor should monitor defects in the outermost corneal layer of the eye for resolution.
The most common ocular side effect is haze. Other ocular side effects include inflammation, fine white lines, dry eye, disruption of surface cells, eye pain, light sensitivity, reduced sharpness of vision, and blurred vision. The risk information provided here is not comprehensive. To learn more, talk to your healthcare provider.
Go to www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Greg Chodaczek or Lynn Lewis